ENTRY       D09761                      Drug
NAME        Mogamulizumab (USAN);
            Mogamulizumab (genetical recombination) (JAN);
            Mogamulizumab-kpkc;
            Poteligeo (TN)
PRODUCT     POTELIGEO (Kyowa Kirin)
FORMULA     C6520H10072N1736O2020S42
EXACT_MASS  146352.7047
MOL_WEIGHT  146442.8849
SEQUENCE    (Heavy chain)
            EVQLVESGGD LVQPGRSLRL SCAASGFIFS NYGMSWVRQA PGKGLEWVAT ISSASTYSYY
            PDSVKGRFTI SRDNAKNSLY LQMNSLRVED TALYYCGRHS DGNFAFGYWG QGTLVTVSSA
            STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP
            SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL
            TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
            QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
            (Light chain)
            DVLMTQSPLS LPVTPGEPAS ISCRSSRNIV HINGDTYLEW YLQKPGQSPQ LLIYKVSNRF
            SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSLLP WTFGQGTKVE IKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (Disulfide bridge: H22-H96, H146-H202, H222-L219, H228-H'228, H231-H'231, H263-H323, H369-H427, H'B22-H'96, H'146-H'202, H'222-L'219, H'263-H'323, H'369-H'427, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  TYPE      Peptide
REMARK      Therapeutic category: 4291
            ATC code: L01FX09
            Product: D09761<JP/US>
EFFICACY    Antineoplastic, Anti-CCR4 antibody
  DISEASE   Mycosis fungoides (CCR4-directed) [DS:H01463]
  TYPE      Monoclonal antibody
TARGET      CCR4 (CD194) [HSA:1233] [KO:K04179]
  PATHWAY   hsa04060(1233)  Cytokine-cytokine receptor interaction
            hsa04062(1233)  Chemokine signaling pathway
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX09 Mogamulizumab
                  D09761  Mogamulizumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Mogamulizumab
                D09761  Mogamulizumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D09761  Mogamulizumab (USAN); Mogamulizumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Chemokine receptors
                CCR4 (CD194)
                 D09761  Mogamulizumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09761
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09761
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09761
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D09761
DBLINKS     CAS: 1159266-37-1
            PubChem: 124490501
///
